Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics Inc (CH:PCJ)
:PCJ
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.32Last Year’s EPS
-0.22Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: ―
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted the successful FDA approval and positive market reception of ZEVASKYN, as well as strategic financial moves to ensure the company's stability. However, delays in patient treatment and increased operating expenses were noted as challenges.Company Guidance
During the Abeona Therapeutics First Quarter 2025 Conference Call, the company provided a comprehensive update on the commercial launch of ZEVASKYN, which was approved by the U.S. FDA as the first autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Key metrics highlighted include the activation of the first Qualified Treatment Center (QTC) at Lurie Children's Hospital of Chicago, and the anticipation of treating the first patient in the third quarter of 2025. Abeona Assist, their patient hub, received inquiries from about 30 patients and families, indicating strong demand. Financially, Abeona reported cash and equivalents of $84.5 million as of March 31, 2025, and expects net proceeds of $152 million from the sale of a priority review voucher (PRV), which will fund operations for over two years. The company reiterated its goal of treating 10 to 14 patients in 2025 and achieving profitability by early 2026, supported by outcomes-based agreements with major payer organizations.FDA Approval of ZEVASKYN
Abeona Therapeutics received FDA approval for ZEVASKYN, the first and only autologous cell-based gene therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).
First Qualified Treatment Center Activated
Lurie Children's Hospital of Chicago has been activated as the first Qualified Treatment Center for ZEVASKYN, enabling patient identification and scheduling.
Strong Initial Market Response
Abeona Assist has received inquiries from approximately 30 patients and families across the U.S. just two weeks after ZEVASKYN's approval.
Positive Financial Outlook
The sale of a Priority Review Voucher (PRV) for $155 million is expected to fully fund operations for over two years, extending the runway through projected profitability in early 2026.
Outcomes-Based Agreements Executed
Abeona has executed outcomes-based agreements with two payer contracting organizations, enhancing potential patient access to ZEVASKYN.
Positive Clinical Data Presentation
At the Society for Investigative Dermatology annual meeting, two late-breaking abstracts were presented highlighting ZEVASKYN's efficacy and safety.
CH:PCJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:PCJ Earnings-Related Price Changes
No data currently available
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Abeona Therapeutics Inc (CH:PCJ) report earnings?
Abeona Therapeutics Inc (CH:PCJ) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Abeona Therapeutics Inc (CH:PCJ) earnings time?
Abeona Therapeutics Inc (CH:PCJ) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Abeona Therapeutics Inc stock?
The P/E ratio of Abeona Therapeutics is N/A.
What is CH:PCJ EPS forecast?
CH:PCJ EPS forecast for the fiscal quarter 2025 (Q2) is -0.32.